Published Paper Details:

Adrenocortical carcinoma (ACC) is a rare, heterogeneous cancer with a poor prognosis and an unclear origin. The incidence of adrenocortical carcinoma (ACC), a rare cancer, ranges from 0.7 to 2.0 incidences per million people per year. 15% of patients with ACC initially receive an incidental diagnosis, however the majority of patients present with excess steroid hormone or abdominal mass effects. Here we summarize the knowledge about diagnosis, epidemiology, pathophysiology, and therapy of ACC. Before surgery and after tumour excision, thorough examinations of clinical, biochemical, and imaging aspects are required for the diagnosis of malignancy. Different tools are suggested after the diagnosis in order to evaluate the prognosis for ACC and create a sound foundation for treatment choices. The total removal of the tumour is the primary option for treatment when the tumour is restricted to the adrenal gland. New targeted medicines, such as IGF-1 receptor inhibitors, have been researched in recent years, but their effectiveness is still restricted. We will have a better grasp of the pathophysiology thanks to the ongoing "omics methods" and next-generation sequencing, which should also result in better treatments.